Hims & Hers Health, Inc. (NYSE:HIMS) Position Increased by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP lifted its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 138.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 90,810 shares of the company's stock after acquiring an additional 52,708 shares during the quarter. ExodusPoint Capital Management LP's holdings in Hims & Hers Health were worth $2,196,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Crewe Advisors LLC acquired a new position in Hims & Hers Health in the fourth quarter worth $28,000. Raleigh Capital Management Inc. lifted its position in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 1,100 shares during the last quarter. Blume Capital Management Inc. boosted its holdings in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 600 shares during the period. Smartleaf Asset Management LLC lifted its holdings in Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after acquiring an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC acquired a new position in Hims & Hers Health in the fourth quarter valued at approximately $38,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 54,153 shares of the firm's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $29.90, for a total transaction of $1,619,174.70. Following the completion of the sale, the insider now directly owns 165,650 shares in the company, valued at approximately $4,952,935. This trade represents a 24.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Oluyemi Okupe sold 11,581 shares of the company's stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $24.44, for a total value of $283,039.64. Following the completion of the transaction, the chief financial officer now owns 118,077 shares in the company, valued at $2,885,801.88. This represents a 8.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 835,884 shares of company stock valued at $31,659,701 over the last three months. Company insiders own 17.71% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on HIMS. BTIG Research started coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a "buy" rating and a $35.00 price target on the stock. Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a research note on Wednesday, April 2nd. Leerink Partners upped their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research report on Tuesday, February 25th. Needham & Company LLC lifted their price target on Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a report on Tuesday, February 25th. Finally, Bank of America increased their price objective on Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a report on Tuesday, March 18th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $38.25.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS traded up $0.32 during trading hours on Friday, hitting $27.13. 16,210,541 shares of the company's stock traded hands, compared to its average volume of 15,109,287. The company's fifty day simple moving average is $38.75 and its two-hundred day simple moving average is $30.37. The company has a market cap of $6.03 billion, a price-to-earnings ratio of 61.66 and a beta of 1.65. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million during the quarter, compared to analysts' expectations of $494.56 million. On average, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.